2RZ Stock Overview A clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Poseida Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Poseida Therapeutics Historical stock prices Current Share Price US$8.91 52 Week High US$9.36 52 Week Low US$1.81 Beta 1.64 1 Month Change 249.22% 3 Month Change 211.15% 1 Year Change 192.93% 3 Year Change 35.95% 5 Year Change n/a Change since IPO -23.14%
Recent News & Updates
Poseida Therapeutics, Inc. Highlights Positive Interim Phase 1 Results for P-Bcma-Allo1 and Preclinical Data for Dual Car-T P-Cd19cd20-Allo1 At the 66Th American Society of Hematology Annual Meeting Dec 10 Roche Holdings, Inc. entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (NasdaqGS:PSTX) from Malin Corporation PLC, Pentwater Capital Management and others for $1.5 billion. Nov 27
Roche Holdings, Inc. entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (NasdaqGS:PSTX) for $930 million. Nov 26
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline Nov 15
New major risk - Share price stability Nov 12
Third quarter 2024 earnings released: EPS: US$0.21 (vs US$0.35 loss in 3Q 2023) Nov 08 See more updates
Poseida Therapeutics, Inc. Highlights Positive Interim Phase 1 Results for P-Bcma-Allo1 and Preclinical Data for Dual Car-T P-Cd19cd20-Allo1 At the 66Th American Society of Hematology Annual Meeting Dec 10 Roche Holdings, Inc. entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (NasdaqGS:PSTX) from Malin Corporation PLC, Pentwater Capital Management and others for $1.5 billion. Nov 27
Roche Holdings, Inc. entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (NasdaqGS:PSTX) for $930 million. Nov 26
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline Nov 15
New major risk - Share price stability Nov 12
Third quarter 2024 earnings released: EPS: US$0.21 (vs US$0.35 loss in 3Q 2023) Nov 08
Poseida Therapeutics, Inc. to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 Nov 06
Poseida Therapeutics, Inc. to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema Oct 26
Poseida Therapeutics, Inc. Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with A T-Cell Engager in a Patient with Relapsed Multiple Myeloma Sep 05
Second quarter 2024 earnings released: US$0.32 loss per share (vs US$0.32 loss in 2Q 2023) Aug 06 Poseida Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $85 million. Aug 06
New major risk - Revenue and earnings growth Jun 07
First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.45 loss in 1Q 2023) May 15
Poseida Therapeutics, Inc., Annual General Meeting, Jun 17, 2024 Apr 28
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma Apr 09
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024 Mar 26
Poseida Therapeutics, Inc. Announces Executive Changes Mar 08
New major risk - Revenue and earnings growth Mar 08
Full year 2023 earnings released: US$1.37 loss per share (vs US$0.89 loss in FY 2022) Mar 08
Poseida Therapeutics, Inc. Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting Dec 11
Third quarter 2023 earnings released: US$0.35 loss per share (vs US$0.92 profit in 3Q 2022) Nov 11 Poseida Therapeutics, Inc. Announces Board Changes
High number of new and inexperienced directors Aug 29
Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.69 loss in 2Q 2022) Aug 09 Poseida Therapeutics, Inc. announced that it has received $24.999999 million in funding from Astellas US, LLC Aug 08
Poseida Therapeutics, Inc. Announces Resignation of Eric Ostertag as Executive Chairman and Retirement from the Board of Directors, Effective February 3, 2023 Feb 01
Poseida Therapeutics, Inc. Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition Dec 12
High number of new and inexperienced directors Nov 17
Poseida Therapeutics, Inc. Announces Program Updates Aug 12 Poseida Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $70 million. Aug 05
Poseida Therapeutics, Inc. Announces Appointment of George M. Church as Chair of Gene Therapy Scientific Advisory Board Jul 27
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from Russell 2500 Index Jun 26
Poseida Therapeutics Appoints Charles M. Baum to Board of Directors May 19
High number of new and inexperienced directors Apr 29
Matthew Spear Informs Poseida Therapeutics, Inc. of His Intent to Resign from Chief Medical Officer Position, Effective April 22, 2022 Apr 08
Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy Feb 24
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 At ASCO Genitourinary Cancers Symposium Feb 18
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors Dec 21
Poseida Therapeutics, Inc. Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting Dec 15
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit Sep 01 Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from Russell 2500 Growth Index
Poseida Therapeutics Presents Encouraging Preclinical Data Across Its Car-T and Gene Therapy Programs At the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting May 12
Poseida Therapeutics Reports Program Updates Mar 12
New 90-day high: €9.65 Feb 26
Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day Feb 25
Catherine Mackey Will Not Stand for Reelection as Director of Poseida Therapeutics, Inc Feb 24
Poseida Therapeutics Appoints Luke Corning to its Board of Directors Dec 19
Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 Dec 06
Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer Nov 03
Poseida Therapeutics Presents CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020 Sep 17 Shareholder Returns 2RZ DE Biotechs DE Market 7D -4.5% -3.5% -2.0% 1Y 192.9% -14.7% 6.9%
See full shareholder returns
Return vs Market: 2RZ exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is 2RZ's price volatile compared to industry and market? 2RZ volatility 2RZ Average Weekly Movement 72.6% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2RZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2RZ's weekly volatility has increased from 37% to 73% over the past year.
About the Company Founded Employees CEO Website 2014 350 Kristin Yarema poseida.com
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC.
Show more Poseida Therapeutics, Inc. Fundamentals Summary How do Poseida Therapeutics's earnings and revenue compare to its market cap? 2RZ fundamental statistics Market cap €882.74m Earnings (TTM ) -€58.23m Revenue (TTM ) €144.58m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2RZ income statement (TTM ) Revenue US$150.86m Cost of Revenue US$172.43m Gross Profit -US$21.57m Other Expenses US$39.19m Earnings -US$60.76m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.62 Gross Margin -14.30% Net Profit Margin -40.28% Debt/Equity Ratio 67.5%
How did 2RZ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 17:48 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Poseida Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alec Stranahan BofA Global Research Justin Zelin BTIG Jennifer Kim Cantor Fitzgerald & Co.
Show 5 more analysts 
